{"id":791170,"date":"2026-02-17T16:20:03","date_gmt":"2026-02-17T16:20:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=791170"},"modified":"2026-02-17T16:20:03","modified_gmt":"2026-02-17T16:20:03","slug":"friedreichs-ataxia-clinical-trial-pipeline-expands-as-10-companies-progress-10-novel-therapies-toward-market-entry-finds-delveinsight-ptc-therapeutics-retrotope-reata-pharmaceuticals-minoryx","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/friedreichs-ataxia-clinical-trial-pipeline-expands-as-10-companies-progress-10-novel-therapies-toward-market-entry-finds-delveinsight-ptc-therapeutics-retrotope-reata-pharmaceuticals-minoryx_791170.html","title":{"rendered":"Friedreich&#8217;s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1771351093.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Friedreich&#039;s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1771351093.jpg\" alt=\"Friedreich&#039;s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Friedreich\u2019s Ataxia \u2013 Pipeline Insight, 2026<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cFriedreich\u2019s Ataxia \u2013 Pipeline Insight, 2026\u201d report provides comprehensive insights about 10+ companies including PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others, developing 10+ pipeline drugs in the Friedreich\u2019s Ataxia pipeline landscape.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Friedreich&rsquo;s Ataxia &ndash; Pipeline Insight, 2026<\/strong>&rdquo; report provides comprehensive insights about 10+ companies developing 10+ pipeline drugs in the Friedreich&rsquo;s Ataxia pipeline landscape. It covers the Friedreich&rsquo;s Ataxia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><em>Explore the latest breakthroughs in the Friedreich&rsquo;s Ataxia treatment landscape. Learn more about the evolving Friedreich&rsquo;s Ataxia pipeline today @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">https:\/\/www.delveinsight.com\/report-store\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Friedreich&rsquo;s Ataxia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In October 2025, <strong>Lexeo Therapeutics released positive interim data for LX2006<\/strong> from SUNRISE-FA Phase 1\/2 and Weill Cornell Phase 1A trials, planning pivotal study in H1 2026.<\/p>\n<\/li>\n<li>\n<p>In July 2025, the <strong>FDA granted Breakthrough Therapy designation to Lexeo Therapeutics&#8217; LX2006<\/strong> based on cardiac and neurologic data.<\/p>\n<\/li>\n<li>\n<p>The leading Friedreich&rsquo;s Ataxia companies include <strong>PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.<\/strong><\/p>\n<\/li>\n<li>\n<p>Promising Friedreich&rsquo;s Ataxia therapies include <strong>EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Download for updates and the latest revolution in Friedreich&rsquo;s Ataxia care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Friedreich&rsquo;s Ataxia Clinical Trials Assessment<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Friedreich&rsquo;s Ataxia Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>RT 001: Retrotope<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Curently in Phase III stage of development for Friedreich&#8217;s ataxia, RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope&rsquo;s novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO).<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Leriglitazone: Minoryx Therapeutics<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Currently in phase II stage of development, Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. This is being developed by Minoryx Therapeutics. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones.<\/p>\n<p style=\"text-align: justify;\"><em>For more information on the Friedreich&rsquo;s Ataxia Emerging Drugs Profile, download <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">DelveInsight&rsquo;s comprehensive Friedreich&rsquo;s Ataxia Pipeline Insight report<\/a>.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>The Friedreich&rsquo;s Ataxia Pipeline Report Provides<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Detailed insights about companies developing therapies for Friedreich&rsquo;s Ataxia, with aggregate therapies developed by each company.<\/p>\n<\/li>\n<li>\n<p>Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Friedreich&rsquo;s Ataxia treatment.<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company&ndash;company and company&ndash;academia), licensing agreements, and financing details for future advancement of the Friedreich&rsquo;s Ataxia market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Learn more about Friedreich&rsquo;s Ataxia Drugs opportunities in our comprehensive Friedreich&rsquo;s Ataxia pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Friedreich&rsquo;s Ataxia Unmet Needs<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Friedreich&rsquo;s Ataxia Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">There are 10+ key companies, such as PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others, developing therapies for Friedreich&rsquo;s Ataxia.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Friedreich&rsquo;s Ataxia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Infusion<\/p>\n<\/li>\n<li>\n<p>Intradermal<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<li>\n<p>Intranasal<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Friedreich&rsquo;s Ataxia products have been categorized under various Molecule types such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Vaccines<\/p>\n<\/li>\n<li>\n<p>Monoclonal Antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Discover the latest advancements in Friedreich&rsquo;s Ataxia treatment by visiting our website. Stay informed @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Friedreich&rsquo;s Ataxia Market Drivers and Barriers, and Future Perspectives<\/a>.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Friedreich&rsquo;s Ataxia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Coverage: Global\u200b<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia companies: PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Therapies: EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination\u200b<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia: Overview<\/p>\n<\/li>\n<li>\n<p>Pipeline Therapeutics<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<\/li>\n<li>\n<p>Late Stage Products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid Stage Products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early Stage Products (Phase I)<\/p>\n<\/li>\n<li>\n<p>Preclinical and Discovery Stage Products<\/p>\n<\/li>\n<li>\n<p>Inactive Products<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Key Companies<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Key Products<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Market Drivers and Barriers<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Future Perspectives and Conclusion<\/p>\n<\/li>\n<li>\n<p>Friedreich&rsquo;s Ataxia Analyst Views<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Arpit Anand<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=friedreichs-ataxia-clinical-trial-pipeline-expands-as-10-companies-progress-10-novel-therapies-toward-market-entry-finds-delveinsight-ptc-therapeutics-retrotope-reata-pharmaceuticals-minoryx\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=friedreichs-ataxia-clinical-trial-pipeline-expands-as-10-companies-progress-10-novel-therapies-toward-market-entry-finds-delveinsight-ptc-therapeutics-retrotope-reata-pharmaceuticals-minoryx\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Friedreich\u2019s Ataxia \u2013 Pipeline Insight, 2026 DelveInsight\u2019s \u201cFriedreich\u2019s Ataxia \u2013 Pipeline Insight, 2026\u201d report provides comprehensive insights about 10+ companies including PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/friedreichs-ataxia-clinical-trial-pipeline-expands-as-10-companies-progress-10-novel-therapies-toward-market-entry-finds-delveinsight-ptc-therapeutics-retrotope-reata-pharmaceuticals-minoryx_791170.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-791170","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/791170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=791170"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/791170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=791170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=791170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=791170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}